Reviewer's report

Title: Superior efficacy of rituximab-based chemoimmunotherapy as a initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Version: 6 Date: 6 May 2015

Reviewer: Xuebin Qin

Reviewer's report:

In this manuscript, Li, et al report the studies of rituximab-based chemoimmunotherapy in Chinese population. Their long-term studies from a single center in China demonstrate a super efficacy of this treatment as an initial therapy in newly diagnosed patients with B cell indolent lymphomas. The studies were well conducted. The results are convincing and very important. It would greatly be helpful for the readers if your paper could be extensively edited by a scientist who is a Native English speaker.

Major Discretionary Revisions:

1) We would rewrite the abstract and clearly present their major results and indication. There are a lot of initials such as MRD, LDH and CLL in abstract, which should be spelled out.

2) Are subpopulations CLL patient? Please make it clearly in abstract.

3) Please spell out the initials when they present first time in the main text.

4) The results in table 2 regarding CLL, FL and other BLPD groups should be mentioned in the text.

5) Please discuss more about Chinese CLL patients in Page 7. For example, there are differences between two populations of CLL patients in response to rituximab-based treatment. Has it reported previously? What are the potential mechanisms for these? Please expand this part of the discussion.

6) Why do they list the table 3? No discussion and explanation for this table 3. If it is not necessary, please delete it. The readers could be easily confused by the table.

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:
I declare that I have not competing interests.